Signal transfer between the protease-activated PAR1 thrombin receptor and membrane-associated heterotrimeric G proteins is mediated by protein-protein interactions. We constructed a yeast signaling system that resolves domain-specific functions of binding from coupling in the G␣ subunit. The endogenous yeast G␣ subunit, Gpa1, does not bind to PAR1 and served as a null structural template. N-and C-terminal portions of mammalian G i2 and G 16 were substituted back into the Gpa1 template and gain-of-function assessed. The C-terminal third of G 16 , but not of G i2 , provides sufficient interactions for coupling to occur with PAR1. The N-terminal two-thirds of G i2 also contains sufficient determinants to bind and couple to PAR1 and overcome the otherwise negative or missing interactions supplied by the C-terminal third of Gpa1. Replacement of the N-terminal ␣-helix of G i2 , residues 1-34, with those of Gpa1 abolishes coupling but not binding to PAR1 or to ␤␥ subunits. These data support a model that the N-terminal ␣N helix of the G␣ subunit is physically interposed between PAR1 and the G␤ subunit and directly assists in transferring the signal between agonist-activated receptor and G protein.
Thrombin plays a central role in blood coagulation and in the cellular response to injury, inflammation, and wound repair. Many of these complex cellular events are initiated by thrombin cleavage of the protease-activated receptor-1 (PAR1) 1 at residues Arg 41 -Ser 42 located within the N-terminal extracellular domain. The new N terminus, Ser 42 -Phe-Leu-Leu-ArgAsn 47 , serves as an intramolecular ligand that binds and activates the body of the PAR1 thrombin receptor (1) (2) (3) . Peptides corresponding to the freshly cleaved N terminus can also activate PAR1 by an intermolecular mechanism (1) . A number of different guanine nucleotide-binding (G) protein ␣-subunits have been shown to couple to PAR1, including members of the G i , G q/16 , and G 12/13 families, but the relative importance of these interactions is not well understood (4 -8) . Recent PAR gene knockout experiments in mice and cloning of two additional thrombin receptors (PAR3 and PAR4) and trypsin/ tryptase receptor (PAR2) have shown that different tissues possess a distinct complement of protease receptors that together determine their respective responses to a variety of proteolytic inputs (9 -13) .
A divergence point in protease receptor signaling is that activation of any particular G␣⅐␤␥ complex will produce two effectors, namely activated G␣ and free ␤␥ (14) . For instance, since phospholipase C-␤ can be potentially activated by either G q or ␤␥, it is conceivable that non-G q subunits may serve the negative function of sequestering ␤␥ to prevent constitutive activation of the phospholipase C-␤ pathway (15) . In platelets, it now seems likely that G q is the primary effector for phospholipase C-␤ rather than free ␤␥. This was demonstrated in G q gene knockout mice (7) , whose platelets lack thrombin-dependent phosphoinositide responses or the ability to aggregate. The G q (Ϫ/Ϫ) platelets retain partial function since they can undergo thrombin-dependent shape change. Therefore, other G␣ subunits such as G i2 and G 12/13 , must necessarily serve as primary effectors for the dramatic cytoskeletal rearrangements that are a prerequisite for platelet aggregation (16) .
Other functions of platelet thrombin receptors are influenced by G i -dependent depression of cAMP levels. The cAMP levels in platelets modulate the activity of platelets; high cAMP levels dampen the response of platelets to agonists and cause attenuation of intracellular Ca 2ϩ levels (17) in part by stimulating Ca 2ϩ efflux by activation of the plasma membrane Ca 2ϩ -ATPase (18) . The role of G i in PAR1 responses has been shown by specific pertussis toxin blockade of G i which significantly reduces SFLLRN-stimulated GTPase activity (19) . It is not known how the G i family members individually regulate adenylyl cyclase, however, the relative abundance is G i2 Ͼ Ͼ G i3 Ͼ G i1 in platelets (20) .
One of the major unanswered questions of thrombin receptor signaling is why does PAR1 couple to only a subset of the available G protein partners in a given cell? Presently, there is limited information regarding the molecular determinants of PAR1-G protein interactions. A single study by Coughlin and colleagues (21) involved replacing internal cytoplasmic loops of the G s -coupled ␤ 2 -adrenergic receptor and the G i -coupled dopamine D 2 receptor with the analogous loops from PAR1. They found that chimeric ␤ 2 -adrenergic and dopamine D 2 receptors bearing the second intracellular loop (i2) from the PAR1 acquire G q -coupling capability. This led them to conclude that the PAR1 i2 loop may provide "coupling instructions" for G q specificity in several different receptor contexts but specific PAR1-G i subunit interactions have yet to be elucidated. With limited high resolution structural data available for receptor-G protein interfaces (22) , most of the focus on the general molecular determinants of coupling preferences centers on mutagenesis of receptor i3 loops and the extreme C-terminal residues of G␣ subunits (23) . For instance, point mutations in the i3 loop of * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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Because there are now high resolution x-ray structures of G␣␤␥ heterotrimers (25, 26) , it is possible to genetically map the solvent-accessible surface of the G protein for the complicity of specific residues in receptor binding and activation. The first such study conducted on a large scale consisted of 100 alanine-substituted solvent-exposed residues of G t that were tested biochemically for impaired interactions with rhodopsin (27) . Only 9 of the 100 substituted residues were believed to affect solely receptor binding. These sites mapped to the Cterminal 41 amino acids of G t which contains the ␤ 6 /␣ 5 motif and crucial 11-residue C-tail which are known to mediate receptor-G␣ interactions (28) . A genetic study of the C-terminal 50 residues of the yeast G␣ subunit, Gpa1, correlated well with the mammalian data (29) . The potential yeast receptor-Gpa1 interface mapped to 4 of the same 9 residues that were identified in G t with an additional 11 residues that were located in the ␣ 5 helix and C-tail. Thus at a genetic level, it appears that the general receptor-G␣ contact surface shares similar architectural features between yeast and mammals.
Given the inherent difficulty in studying structure-function relationships of specific PAR1-G protein complexes in mammalian cells, we developed a more simplified receptor-G protein yeast model system (30 -32) that could be used to elucidate mechanistic details of PAR1-G protein coupling. In the studies presented here, we have replaced the endogenous yeast receptor with the human PAR1 thrombin receptor and obtained high affinity agonist binding and functional coupling to co-expressed G proteins. Determinants of PAR1-G protein coupling are separable from binding activity and are found throughout a large interface that encompasses both N-and C-terminal regions of the G␣ subunit. Our data are also consistent with a model that the N-terminal ␣N helix of the G␣ subunit inserts between PAR1 and the G␤ subunit and mediates binding and coupling between agonist-activated receptor and G protein. These genetic and biochemical studies further underscore the advantage of using yeast where one can reconstitute a simple signaling unit consisting of ligand-receptor-G-protein that can be tested for functional properties in isolation from all other mammalian proteins.
EXPERIMENTAL PROCEDURES
Materials-Human ␣-thrombin (3433 NIH units/mg) was from Haematologic Technologies (Essex Junction, VT). Restriction enzymes and Vent DNA polymerase were from New England Biolabs (Beverly, MA).
Plasmid Construction-The ste2::URA3-hisG disrupter construct, pSte2KO, was assembled from 5Ј (1480 bp) and 3Ј (700 bp) flanking sequences of STE2 with the 5000-bp hisG-URA3-Kan r -hisG fragment from pSE1076 (gift of E. Elion) inserted between them in pUC19. The STE2 expression vector, p112-H6T7Ste2⌬300, is derived from the 2-m TRP1 plasmid, YEplac112 (33) . The 5Ј-untranslated region of STE2 was amplified by PCR to create a 544-bp SphI-XbaI fragment that was placed into corresponding sites of pUC19 and designated p19 -5ЈUTRH6. The fragment of the STE2 gene encoding amino acid residues Ala 4 to Thr 297 was amplified by PCR and placed into the XbaIKpnI sites of p19 -5ЈUTRH6 to create p19-H6T7Ste2. PCR was then used to amplify 200 bp of the 3Ј-untranslated region of STE2. This 200-bp fragment was ligated into KpnI-EcoRI sites of p19-H6T7Ste2 to create p19-H6T7Ste2⌬300. The 1680-bp SphI-EcoRI fragment was then shuttled into the corresponding sites of YEplac112 and YEplac195 (2 m URA3 (33)) to create p112-H6T7Ste2⌬300 and p195-H6T7Ste2⌬300, respectively. The p112-STE2 vector contains the 2010-bp SphI-EcoRI wild-type STE2 fragment amplified by PCR.
The thrombin receptor expression vector, p112-H6PAR1⌬379 was created by inserting the region of hPAR1 encoding residues Leu 38 -Glu 377 into the BamHI and KpnI sites of p112-H6T7Ste2⌬300. PCR was used to amplify the cDNA of hPAR1 subcloned into the SalI sites of pBluescript (gift of S. Coughlin). This BamHI-KpnI fragment was subcloned into the analogous sites of p112-H6T7Ste2⌬300 to make p112-H6PAR1⌬379. An extra two codons (Met 378 -His 379 ) were added to the C terminus to accommodate a KpnI restriction site.
The hPAR1 gene comprising residues Leu 38 -Tyr 420 was amplified with PCR primers (ϩ) 5Ј-TACTCTCGCGATCTAGACGCAGGCCAGA-ATCAAAAGCA-3Ј and (Ϫ) 5Ј-TCACTATGCATGGATCCGTATATGCT-GTTATCCAGGTTACT-3Ј. A 1205-bp NruI-NsiI fragment was subcloned into the HincII-PstI sites of p19H6T7Ste2⌬300 (1680-bp H6T7Ste2⌬300 fragment subcloned into the SphI-EcoRI sites of pUC19). The 949-bp PstI-KpnI fragment was then subcloned into the corresponding sites of p112-H6PAR1⌬379 to create p112-H6PAR1. This PAR1 construct has the 5 C-terminal amino acids Lys 421 -Lys-Leu-LeuThr 425 , replaced with GSMQ. The high copy number yeast expression vector pRS426-GPA1 (URA3 2 m) is the 1900-bp EcoRI fragment of GPA1 with flanking 5Ј and 3Ј GPA1 regulatory elements subcloned into pRS426 (gift of S. DeSimone and J. Kurjan). The pPGK-G i2 vector expresses full-length rat G i2 and the pPGK-G i2 -gpa1 vector expresses a chimera comprising residues 1-212 of G i2 joined to residues 330 -472 of Gpa1 (34) . pPGK-␣N-i2 expresses a chimera that fuses Gpa1 residues 1-42 to residues 35-355 of G i2 . This was made by PCR amplification of the respective regions from the Gpa1 and G i2 vectors, and subcloning them into pPGK. p195-Gpa1-i2 expresses a chimera encoding residues 1-329 of Gpa1 joined to residues 213-355 of G i2 under the control of the GPA1 promoter in the 2-m URA3 plasmid, YEplac195 (33) . This was made by PCR amplification of the corresponding GPA1 coding sequence plus 200 bases upstream, ligation to the corresponding G i2 sequence, and subcloning into YEplac195. p195-Gpa1-16 expresses a chimera encoding residues 1-329 of Gpa1 joined to residues 220 -374 of G 16 , under the control of the GPA1 promoter. p195-Gpa1-16 was made by replacement of the G i2 sequence in p195-Gpa1-i2 with the sequence encoding residues 220 -374 of G 16 . G 16 was amplified from the pCISG16 template by PCR (gift of M. Simon).
Construction of Yeast Strains-The yeast strains (Table I) were derived from either W303a or a protease-deficient strain, BJ2168. The chromosomal STE2 allele was deleted by homologous recombination (35) at 5Ј-and 3Ј-flanking regions with pSte2KO. The BamHI-PvuII fragment of pSte2KO containing ste2⌬hisG-URA3-hisG, was used to transform EY957 and BJ2168, and ura3 Ϫ derivatives were recovered by counterselection on 5-fluoroorotic acid media (36) to yield KY1 and KY15, respectively. The chromosomal G␣ gene, GPA1, was deleted in strain EY1262 (gift of E. Elion) using the knockout construct pSK-IPCR-URA3 (gift of S. DeSimone) digested with EcoRI. A ura3 derivative was made by counterselection on 5-fluoroorotic acid media by previously published methods (37) to make KY187 in far1-deficient genetic backgrounds.
␤␥ Sequestration Determinations in Yeast-Yeast strain KY187 (gpa1 ura3 his3 FUS1-HIS3) carrying a 2-m URA3 vector with a G␣ subunit gene was grown in synthetic dextrose media deficient for uracil at 250 rpm and 30°C to ϳ1 ϫ 10 6 cells/ml at A 600 ϭ 0.4. Cells were pelleted, washed in sterile distilled water, and resuspended to a concentration ϳ2 ϫ 10 4 cells/ml in synthetic dextrose media deficient for uracil and histidine. The cells were grown as above, and assayed for absorbance at 600 nm for 2-3 days. Slow growing cultures were split 2-fold, and histidine was added to a final concentration of 20 mg/liter to one set of cultures. Growth and absorbance assays were continued to stationary phase for the cultures with histidine.
Expression of PAR1 and G Proteins in Yeast-Cultures (5 ml) of yeast strains harboring His 6 T7-tagged PAR1 expressed from high copy number (2 m TRP1) vectors were grown to saturation in CAA-TRP media (1 liter contains 6 g of casamino acids, 2% glucose, 1.7 g of yeast nitrogen base, 5 g of ammonium sulfate, 40 mg of adenine, and 20 mg of uracil) at 30°C. If coexpression of PAR1 and G-protein was required, the G-protein was expressed from a second vector (2-m URA3) using media lacking uracil and tryptophan. A dilution of 1:1000 of the overnight culture was made into fresh CAA-TRP (or CAA-TRP-URA) media and grown at 30°C to a density of 1-1.5 A 600 . All further steps were carried out at 4°C. Cells from 2-liter cultures were harvested by centrifugation for 30 min at 3,300 ϫ g, and resuspended in 200 ml of lysis buffer (20 mM KPO 4 , pH 7.0, 1 mM MgCl 2 , 10% glycerol, 1 mM EDTA, and 1ϫ protease inhibitor mixture (38) ). Glass beads (0.5 mm) were then added to the cell suspension (50% v/v) and cells were disrupted in a stainless steel bead beater (Biospec, Bartlesville, OK) equipped with ice-water jacket. The cell lysate was centrifuged for 30 min at 8,000 ϫ g and the supernatant (180 ml) subjected to ultracentrifugation at 150,000 ϫ g for 1 h. The crude membrane pellets were resuspended in 10 ml of storage buffer (20 mM KPO 4 , pH 7.5, 100 mM NaCl, 10% glycerol) by sonication for 1 min at a power setting of 4 -7 on a Branson sonicator and stored as 1 -ml aliquots at Ϫ80°C. Yeast membrane proteins were maintained at 10 -15 mg/ml for stability.
Ni-chelation Chromatography of His 6 -tagged PAR1-G Protein Complexes-A 5-ml iminodiacetic acid (IDA)-Sepharose column (Novagen)
was charged with 10 ml of 100 mM NiSO 4 and equilibrated with 50 ml of 5ImBB (5 mM imidazole, 500 mM NaCl, and 20 mM Tris-HCl, pH 7.9). Typically, 12 mg of crude yeast membrane protein containing H6PAR1/ G-protein was applied to the IDA affinity column and recycled for 2 h at 0.38 ml/min. Bound H6PAR1/G-protein was washed with 25 ml of 5ImBB/0.1C (5ImBB ϩ 0.1% CHAPS, w/v), and eluted with 15 ml of 100ImBB/0.1C (100 mM imidazole, 500 mM NaCl, and 20 mM Tris-HCl, pH 7.9, 0.1% CHAPS, w/v). Alternatively, 0.1% SDS was substituted for 0.1% CHAPS in the wash (5ImBB/0.1S) and elution buffers (100ImBB/ 0.1S). The affinity purified H6PAR1/G-protein was dialyzed against 2 ϫ 4 liters of 0.05% SDS, 5 mM Tris-HCl, pH 7.5, in 12-14-kDa M r cut-off dialysis bags. 1-ml aliquots of dialyzed H6PAR1/G-protein were transferred to 1.6-ml polypropylene tubes, evaporated to dryness with a Speed-Vac concentrator (Savant), and stored at Ϫ20°C. These dried fractions were reconstituted in Laemmli sample buffer and resolved by 10% SDS-PAGE and Western analysis.
Radioligand Binding Assays-The high affinity peptide agonist, 56 (Ala-(pF-Phe)-Arg-cyclohexylalanine-homoarginine-Tyr-NH 2 ) was a gift from Merck (39) . Compound 56 was iodinated on tyrosine and purified to radionuclide purity by high performance liquid chromatography by previously described methods (40) . The 125 I-56 peptide was dissolved in 10% dimethyl sulfoxide, 90% 50T/0.1C (50 mM Tris-HCl, pH 7.5, 10 mM MgCl 2 , 0.1% CHAPS, w/v) as a 50 nM stock solution just prior to use. TRAP peptide (SFLLRN-NH 2 ), and NAc-Ala-(pF-Phe)-Arg-cyclohexylalanine-Arg-Tyr-NH 2 (NAc-TRAP) were synthesized and purified by M. Berne in the Tufts University Analytical Core Facility. Peptides were stored as 50ϫ stock solutions in dimethyl sulfoxide at Ϫ20°C.
His 6 T7-tagged receptor-G-protein complexes were partially purified from crude yeast membranes using a ratio of 200 g of loaded protein/25 l of Ni-IDA-Sepharose beads. Typically, 5 mg of membrane protein at 10 -15 mg/ml was added to 625 l of Ni-IDA beads in 6.25 ml of 5ImBB. The mixture was rocked at 4°C for 1 h and washed with 2 ϫ 14 ml of 5ImBB/0.1C, then 2 ϫ 14 ml of 50T/0.1C. The washed Ni IDA-H6T7-receptor(G protein) beads were suspended in 6.25 ml of 50T/0.1C, and 250-l aliquots distributed into 1.6-ml polypropylene tubes. Binding assays were done in 500-l systems containing 25 l of Ni-IDA-H6PAR1(G protein) beads, 1 nM to 1 mM agonist/antagonist peptide, 0.7-0.9 nM GTP␥S Binding Assays-We adapted the assay used for mammalian cells (41) to our yeast system with a few modifications. The H6PAR1(Gprotein) complexes were prepared as above except we used a ratio of 175 g of loaded protein per 15 l of Ni-IDA beads and two washes with 14 ml of TE-HCl (10 mM triethanolamine-HCl, pH 7.5) instead of 50T/0.1C. Assays were performed in 200-l volumes and consisted of 15 l of Ni-IDA-H6PAR1(G-Protein) beads suspended in 150 l of TE-HCl, 5 l of 0.25 nM to 250 M peptide agonist in 20% dimethyl sulfoxide, 80% TE-HCl, and 40 l of 5ϫ AB (250 mM TE-HCl, 25 mM MgCl 2 , 5 mM EDTA, 5 mM dithiothreitol, 500 mM NaCl, 2.5 nM GTP-␥-35 S), Ϯ 5 l of 10 M GDP in TE-HCl. Reaction mixtures were incubated at 30°C for 1 h in 10 ϫ 75-mm polypropylene tubes with shaking at 250 rpm. Assays were terminated by addition of 2.5 ml of ice-cold WB (50 mM Tris-HCl, pH 7.5, 5 mM MgCl 2 ) and filtered through 25-mm GF/C filters. Filters were washed with 2 ϫ 2.5 ml of WB and bound GTP-␥- 35 S quantitated by ␤-scintillation counting as described (41) .
Antibodies and Flow Cytometry-The polyclonal antibody (SFLLRAb) directed against the PAR1 ligand region, residues S 42 FLLRNP-NDKYEPF 55 C, was generated as described previously (42) . The T7-tag mouse monoclonal antibody (T7-Ab) directed against residues MASMT-GGQQM was purchased from Novagen. AS-Ab is the rabbit polyclonal antibody (NEN Life Science Products Inc.) raised against the G t Cterminal peptide, KENLKDCGLF, which reacts with G i2 (43) . Immunoblotting was done as described previously (44) . The Gpa1-Ab is a rabbit polyclonal antibody made against full-length Gpa1 (45) . In flow cytometry experiments, yeast cells were fixed in 5% formaldehyde for 2 h at 25°C prior to fluorescent staining. After 2 successive washes with WB2 (100 mM K 2 HPO 4 , 100 mM KH 2 PO 4 , 1.2 M sorbitol) ϳ10 7 cells were resuspended in 1 ml of WB2 containing 88 units of Lyticase (Roche Molecular Biochemicals) and incubated for 30 min at 30°C in a rollodrum to remove the yeast cell wall and form spheroplasts. Intact spheroplasted cells were stained with either the T7-Ab (final concentration 1 g/ml), or SFLLR-Ab (final concentration 2 g/ml) for 30 min at 25°C in the presence or absence of 0.1% Tween 20. This was followed by incubation with secondary antibody for 30 min at 25°C using either goat anti-mouse IgG-fluorescein isothiocyanate (10 g/ml; DAKO) or goat anti-rabbit IgG-fluorescein isothiocyanate (6 g/ml; Zymed Laboratories Inc.). Cells were analyzed for fluorescence with a FACScan flow cytometer (Becton Dickinson).
RESULTS AND DISCUSSION
Expression and Thrombin Cleavage of PAR1 in Yeast Membranes-PAR1 is a type I integral membrane protein which has a cleavable N-terminal hydrophobic signal sequence that properly orients the receptor in the lipid bilayer (1). The type III endogenous Ste2 ␣-mating factor receptor uses the first transmembrane ␣-helix as a signal peptide which is not cleaved by a Fig. 1, lane 5 , H6PAR1 localizes to the membrane fraction (UP) and has a relative molecular mass of 34 kDa. The SFLLR-Ab also stains three endogenous yeast proteins migrating at 66, 49, and 46 kDa. Noncovalent higher order H6PAR1 species such as dimer (70 kDa) and tetramer (150 kDa) resist disassociation by 1% SDS as has been observed with other receptors (47) but can be minimized by the inclusion of 4 M urea in the sample buffer (Fig. 1, lane 7) . Since the observed molecular mass is 12 kDa smaller than expected (46 kDa) we wanted to rule out C-terminal proteolysis or premature translation termination of the heterologously produced PAR1. To address this mass discrepancy, we expressed a shortened version of the receptor (H6PAR1⌬379) that lacked the C-terminal cytoplasmic domain, residues 380 -425. As shown in Fig. 1, lane 12 , the H6PAR1⌬379 is also targeted to the membrane fraction and has a monomeric molecular mass of 30 kDa which is 4 kDa smaller than the nearly full-length H6PAR1 (expected ⌬molec-ular mass is 5 kDa). This indicates that PAR1 is full-length but migrates anomalously fast on SDS-polyacrylamide gel electrophoresis. Extensive digestions of H6PAR1 with glycopeptidase F failed to show any shift in size thereby ruling out N-linked glycosylation (data not shown).
One test of PAR functionality is the ability of the cognate protease to recognize and cleave the receptor at the correct cleavage site. As shown in Fig. 1 , we demonstrated that yeastexpressed PAR1 can be cleaved at the Arg 41 -Ser 42 peptide bond by nanomolar thrombin. Treatment of H6PAR1 with 5 nM thrombin results in essentially complete loss of the T7-epitope (Fig. 1, lane 8) and the expected slight downward shift in mass is detected by the SFLLR-Ab (Fig. 1, lane 6) . Likewise, cleavage of H6PAR1⌬379 at the Arg 41 site with 1 nM thrombin causes Ͼ97% loss of the T7-epitope (Fig. 1, lane 13) . Further characterization of plasma protease cleavage sites and cleavage kinetics of the yeast-produced receptor are presented in a separate report (42) .
Cellular Localization of PAR1 in Yeast-Flow cytometry was used to determine whether PAR1 is targeted to the yeast plasma membrane and in the proper orientation. As positive and negative controls, we first examined the localization of H6T7Ste2 (KY34) and H6Ste2 (KY27) which lacks the T7 epitope. As shown in Fig. 2C , the median fluorescence intensity of KY34 increased 1.5-fold relative to KY27 in the absence of Tween 20. When these cells were permeabilized with 0.1% Tween 20, the median fluorescence intensity increased to 2.6-fold relative to KY27. Therefore, the further increase in fluorescence of the Tween 20 permeabilized KY34 cells relative to the intact KY34 cells indicates that the highly expressed H6T7Ste2 is distributed both on plasma membrane and within membrane compartments located in the cytoplasm. Examination of T7-Ab-stained KY34 by in situ immunofluorescence showed that H6T7Ste2 stains as a uniform coating on the plasma membrane and as bright-stained objects within the cytoplasm (data not shown). The cellular distribution of H6PAR1 (KY91) is similar to that of H6T7Ste2. In non-permeabilized cells, the median fluorescence intensity of KY91 increases 1.8-fold ( Fig. 2A ) and 1.5-fold (Fig. 2B) relative to control cells using the SFLLR-Ab and T7-Ab, respectively. In permeabilized cells, the median fluorescence intensity increases 3.4-and 3.8-fold relative to control cells, respectively. Thus, PAR1 is also distributed on both plasma membrane and intracellular membranes. Since the SFLLR and T7 epitopes are located in the N-terminal exodomain of the H6PAR1, the staining of intact yeast spheroplasts by the two antibodies also indicates that the receptor is in the proper orientation in the plasma membrane for a type III integral membrane protein.
Co-Purification of G␣ Subunits with PAR1-Next, we examined the ability of co-expressed G␣ subunits to bind His 6 -tagged PAR1. The first G␣ subunit to be tested for binding to PAR1 was full-length G i2 . The yeast-expressed G i2 comigrates with authentic G i2 from platelet membranes at 38 kDa (Fig. 3) . The yeast membranes containing H6PAR1 plus G i2 subunit were passed over Ni-IDA columns and extensively washed with buffer containing 0.1% CHAPS detergent. Bound H6PAR1⅐G i2 complexes were eluted with 100 mM imidazole and Western analysis performed with the SFLLR-Ab to detect the presence of H6PAR1. As shown at the bottom of Fig. 3, lane 4 , H6PAR1 is eluted from the Ni-IDA resin by 100 mM imidazole and migrates as a 34 kDa band. G i2 copurifies with H6PAR1 as detected by the AS-Ab (Fig. 3, lane 4) . G i2 is not retained on the Ni-IDA resin in the absence of co-expressed H6PAR1 consistent with specific G i2 /H6PAR1 binding occurring under these conditions (Fig. 3, lane 6) .
We determined that the yeast Gpa1 subunit does not copurify with H6PAR1. Since the genomic GPA1 allele gives low levels of Gpa1 protein expression, we overexpressed Gpa1 5-10-fold over background levels using a high copy number plasmid (Fig. 3, lane 14) . As shown in Fig. 3, lane 15 , even these high levels of Gpa1 do not bind to H6PAR1. Since the fulllength Gpa1 does not bind to H6PAR1 it was used as a null structural template in the subsequent chimera studies. We could then add back portions from authentic couplers such as G i2 or G 16 and test for gain of binding in order to delineate domain-specific functions within the G␣ subunits. The chimeric G␣ subunits were constructed using C-and N-terminal portions of mammalian G i2 , G 16 , and the endogenous yeast Gpa1: Gpa1-i2, Gpa1-16, and G i2 -gpa1 (Fig. 6) . The Gpa1-i2 chimera comprises residues 1-329 of the yeast Gpa1 and residues 213-355 of G i2 (34) . The Gpa1-16 chimera comprises residues 1-329 of Gpa1 joined to residues 220 -374 of G 16 . The reverse G i2 -gpa1 chimera comprises residues 1-212 of the G i2 joined to residues 330 -472 of Gpa1. The chimeric junction (Fig. 6 ) is located at the highly conserved switch II region (25) . To simplify interpretation of the Western data, we deleted the genomic GPA1 allele (Fig. 3, lane 16 ) and expressed the Gpa1 chimeras in the gpa1 null background. The chimeric G proteins, Gpa1-i2 and Gpa1-16, were expressed in yeast, and both co-purify with H6PAR1 (Fig. 3, lanes 10, 11, and 13, respectively) . Therefore, the C-terminal third of G i2 or G 16 (48) is sufficient to confer binding to PAR1 although the majority of the chimera is Gpa1. The reverse chimera, G i2 -gpa1, which had been reported in earlier studies to be expressed in yeast (34) is not detected by the AS-Ab or Gpa1-Ab. However, the G i2 -gpa1 reverse chimera was found to couple efficiently to PAR1 by functional assays (see below).
Thrombin Receptor Agonist Peptide (TRAP) Binding to PAR1-G Protein Complexes-Next, we ascertained whether the heterologously produced PAR1-G protein complexes could bind SFLLRN peptide ligand. We prepared a high affinity radioligand, 125 I-56, that has an EC 50 of 30 nM for the human platelet PAR1 (39) . Membrane fractions containing H6PAR1-G protein complexes were bound to Ni-IDA beads and washed extensively to reduce nonspecific binding of the hydrophobic 125 I-56 peptide ligand. As shown in Fig. 4 , SFLLRN peptide displaces 125 I-56 from H6PAR1/G i2 and H6PAR1/G i2 -Gpa1 with IC 50 values of 2-3 M (Table II) . The maximal amount of bound 125 I-56 is in the range of 10 -13 pM (Table II) . Cells expressing Gpa1 along with H6PAR1 gave an IC 50 value of 54 M for the SFLLRN ligand. Since the endogenous Gpa1 does not bind H6PAR1 under these conditions, this 22-fold poorer IC 50 value probably reflects the low affinity state of PAR1 in the absence of bound G protein. For comparison, 10-fold shifts in K D were seen with ␣-factor peptide binding to Ste2 when GTP␥S was added to dissociate bound Gpa1/␤␥ (49) . In a negative control experiment, NAc-TRAP peptide, which does not bind the receptor, could not displace 125 I-56 from H6PAR1/G i2 at concentrations as high as 250 M. In a second negative control experiment using yeast extracts that lacked the thrombin receptor, H6T7Ste2 was overexpressed and membrane extracts bound to Ni-IDA beads as before. In this case, very low levels (0.2 pM) of 
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125 I-56 bind to Ni-IDA-H6T7Ste2 and this level is unaffected by SFLLRN peptide (Fig. 4) .
Functional Coupling of PAR1-G Protein Complexes Expressed in Yeast-Now that we had detected binding between PAR1 and G␣ subunits, we tested whether the complexes would undergo nucleotide exchange (19, 41) in response to the SFLLRN agonist. We devised a GTP-␥- 35 S nucleotide exchange assay that was optimized for our His 6 -tagged PAR1. As shown in Fig. 5 , addition of SFLLRN to the H6PAR1⅐Gpa1-16, H6PAR1⅐G i2 -gpa1, or H6PAR1⅐G i2 complexes stimulate binding of GTP-␥- 35 S with EC 50 values ranging from 1.8 to 4.4 M ( Table II) . Addition of GDP displaces Ն96% of bound GTP-␥- 35 S from the SFLLRN-activated H6PAR1⅐G i2 complex (Fig. 5C ). Similar reductions are seen for the H6PAR1⅐G i2 -Gpa1 and H6PAR1⅐Gpa1-16 complexes (data not shown). There is no SFLLRN-dependent binding of GTP-␥- 35 S to Gpa1 coexpressed with H6PAR1 (Fig. 5C ), as expected since Gpa1 does not bind PAR1. Coupling by G i2 -gpa1 shows that the N-terminal twothirds of G i2 provide sufficient functional interactions with PAR1, and that the C terminus of Gpa1 can substitute for G i2 to provide the essential C-terminal coupling determinants. Conversely, the Gpa1-16 chimera couples to PAR1 thus demonstrating that the C terminus of G 16 can also provide sufficient positive interactions to dominate the otherwise deficient interactions occurring at the N terminus of Gpa1 (48) . Most surprisingly, PAR1 does not couple to the bound Gpa1-i2 chimera despite having the appropriate C-terminal ␤6/␣5 motif (Fig. 6) . This is also a first indication that N-terminal regions of the G␣ subunit can supersede C-terminal regions in the control of G protein-PAR1 coupling.
The ␣N helix is the prime candidate within the N-terminal two-thirds of the G␣ subunit for mediating coupling between the receptor and G protein. This ␣N helix is the site of Nterminal lipid modification of the G␣ subunit and is expected to orient the G protein heterotrimer in juxtaposition to the plasma membrane and the intracellular loops of the G proteincoupled receptors (25) . Early support for this model was provided by Hamm et al. (50) who demonstrated that an 8 -23 G t peptide blocked full-length G t from binding rhodopsin. The first direct evidence for this topological model was provided by Neubig and colleagues (51) who detected cross-linking between intracellular loops from the ␣ 2 -adrenergic receptor and the N-terminal 16 residues of the G i/o subunit. In order to ascertain whether the ␣N-helix (residues 6 -30) of G i2 may contain the N-terminal coupling determinants, we replaced G i2 residues 1-34 with the corresponding residues from Gpa1 (residues 1-42) to make the ␣N-i2 chimera. This chimera retains strong binding to H6PAR1 by Ni-IDA chromatography (Fig. 3, lane 8) , but does not couple to PAR1 (Fig. 5B) unlike full-length G i2 . To our knowledge, this is the first report that receptor-G protein coupling determinants are located within the ␣N helix of a G␣ subunit and is contrary to the dogma that C-terminal G␣ regions are paramount for coupling interactions.
In assessing the fidelity of coupling between our heterologously expressed PAR1/G␣ subunit pairs, we examined the analogous parameters derived from mammalian systems. The SFLLRN-dependent nucleotide exchange EC 50 values which we obtained for individual G i2 , Gpa1-G 16 , and G i2 -Gpa1 subunits coupled to PAR1 agree nicely with those values derived from platelets. Seiler et al. (19) obtained EC 50 values of 1-3 M for GTPase activation with platelet membranes. Since platelet extracts contain at least 9 G␣ subtypes (52) these EC 50 values must be considered to be an aggregate measurement although inhibition with pertussis toxin indicated that the majority of the GTPase activity derives from G i subunits. In the studies presented here, we have made the first quantitative measurements of coupling between isolated PAR1-G protein pairs.
Sequestration of Yeast ␤␥ by G␣ Subunits-Receptor-bound heterotrimeric G proteins consist of GDP-G␣⅐␤␥ complexes. G␣ subunits do not support coupling to G protein-coupled receptors in the absence of ␤␥ subunits (53) . Since the G i2 , G i2 -gpa1, and Gpa1-G 16 chimeras in complex with PAR1 undergo high-affinity SFLLRN-dependent nucleotide exchange, this would indicate that the yeast ␤␥ dimer associates at least transiently with these G␣ subunits. Indeed, if null mutants are made by deleting either the yeast STE4 or STE18 genes which encode the yeast ␤ and ␥ subunits, respectively, one does not observe high affinity binding of ␣-factor peptide to the Ste2 receptor (49) . The intersubunit contacts between G␣ and ␤ subunits are highly conserved between yeast and mammals (70% identity) and are well defined by x-ray structural analysis (25, 26) . The major G␣ switch I-II interface buries 1800 Å 2 of surface area with the side of the ␤ subunit (Fig. 6 ) and undergoes substantial conformational changes upon nucleotide exchange (25) . A secondary interface between the top side of the ␤ subunit and the ␣N helix of G␣ provides an additional 900 Å 2 of binding surface.
To directly test for the ability of the hybrid mammalian G␣ subunits to bind the yeast ␤␥ dimer we employed a ␤␥ sequestration assay. An essential function of the yeast G␣ subunit, Gpa1, is to tightly sequester ␤␥ and thus prevent it from activating the MAP kinase scaffolding protein complex, Ste5⅐Ste20⅐Cdc24 (54, 55) . Even minor leakage of free ␤␥ away from G␣ results in activation of the MAP kinase cascade and mitotic arrest (34) . The growth arrest phenotype is dependent on the activity of the Far1 protein. The opposite phenotype occurs with our genetically altered yeast strain KY187 (far1⌬ lys2::FUS1-HIS3 his3⌬200 gpa1⌬). This strain has been engineered so that growth in histidine-deficient media is dependent on ␤␥ activation of the MAP kinase pathway which results in transcription of an integrated FUS1-HIS3 reporter gene (56) . The growth arrest that would normally occur due to activation of the MAP kinase pathway is prevented by deletion of the Fig. 4 . GTP-␥- 35 S binding experiments were conducted as described in the legend to Fig. 5 FAR1 gene in KY187. Sequestration of ␤␥ by a G␣ subunit results in slow growth (long doubling time) due to failure to activate the MAP kinase pathway and transcription of the FUS1-HIS3 reporter gene. As shown in Table III , plasmidexpressed Gpa1 sequesters ␤␥ and strongly retards growth (Ͼ15 h doubling time) in the absence of histidine. Addition of histidine to the media bypasses the necessity for the MAP kinase-dependent transcription of the FUS1-HIS3 reporter and restores growth (3.9-h doubling time). Conversely, in the absence of Gpa1 (vector alone), the ␤␥ dimer freely activates the MAP kinase pathway, which results in the transcription of FUS1-HIS3. This causes a marked increase in growth (3.4-h doubling time) in histidine-deficient media. Expression of fulllength G i2 in KY187 results in little or no sequestration of ␤␥ as determined by our growth assay (Table III) . Another study (34) had previously demonstrated very weak sequestration of yeast ␤␥ by G i2 in FAR1 ϩ yeast strains using a mitotic arrest assay. In order to determine which domains of the G␣ subunit confer the ability to associate tightly with yeast ␤␥, the array of G␣ hybrids were tested in the KY187 yeast strain. The G i2 -gpa1 chimera does not sequester ␤␥ indicating that the Nterminal two-thirds of G i2 does not provide sufficient positive interactions with yeast ␤␥. Conversely, the Gpa1-i2 and ␣N-i2 chimeras provide full sequestration of ␤␥ (Table III) . This clearly indicates that the positive interactions afforded by the ␣N helix are necessary for sequestration of yeast ␤␥ despite the remainder of the G␣ subunit being comprised of G i2 including the switch I-II interface (Fig. 6) . Surprisingly, unlike Gpa1-i2, the Gpa1-16 chimera does not sequester yeast ␤␥ irrespective of the 90% identity between Gpa1 and Gpa1-16 at positions that directly contact ␤␥ in both N-terminal and switch I-II regions. Therefore, negative interactions from the C-terminal third of the G␣ subunit may overcome positive interactions that exist in the N-terminal interface region. Together, these data would imply that the forces holding together the heterotrimer are highly cooperative as suggested by x-ray structural analyses (25, 26) .
Dual Function of the G␣ Subunit ␣N Helix in Binding to ␤␥ and in Coupling to Receptor-The biochemical and genetic data presented here are the first evidence that the ␣N helix of the G␣ subunit plays a critical role in mediating proper coupling between G protein and receptor. The ␤␥-sequestration data demonstrate that binding determinants in the N-terminal ␣N helix are necessary but not sufficient for tight binding to the ␤␥ dimer. Based on the x-ray structure of G␤␥ t (25) , seven residues from the yeast Ste4 ␤ subunit would comprise the binding surface for interaction with six residues from the bottom face of the ␣N helix of G␣ (Fig. 6) . Three of the seven Ste4 N-terminal interface residues are non-conserved relative to mammalian ␤ 1   FIG. 6 . Domain-specific interactions between PAR1 and G␣ subunits. Composition of the hybrid G␣ subunits and their characteristics related to the heterotrimeric G protein structure (25) . Labels on the G␣ subunit are as follows: ␣N is the N-terminal ␣-helix involved in receptor and ␤␥ coupling, ␣B domain is a unique Gpa1 domain of unknown function, SwII is part of the G␣ switch I-II interface that binds ␤␥ and undergoes nucleotide-dependent conformational changes, the ␤6/␣5 region is a C-terminal region involved in receptor coupling. b Yeast culture growth over 2-3 days established only a lower limit of the doubling time.
c ND, not determined.
(Leu 3 Asn, Phe 3 Lys, Phe 3 Lys). These substitutions could prevent association with non-Gpa1 subunits and thereby explain the inability of full-length G i2 to sequester yeast ␤␥. Alanine scanning mutagenesis confirmed the importance of the cognate ␣N helix residues of G t in binding mammalian ␤␥ (27) . Point mutations of four out of six ␣N residues that contact ␤ were able to disrupt G t binding to the ␤␥ dimer. In marked contrast, the alanine scan failed to detect deleterious effects on rhodopsin binding to G t upon mutation of the interspersed surface-exposed residues of the ␣N helix. Likewise, in our studies here, the ␣N-i2 chimera bound tightly to PAR1 despite having several non-conserved substitutions at surface-exposed residues on the ␣N helix. The ␣N-i2 chimera did not couple to PAR1, however, indicating that ␣N helix provides fine determinants of G protein-receptor signaling and is not simply docking the G protein to the receptor-membrane interface.
